EU Relapsing-Remitting MS Trials Should Have Active Controls - CPMP
Executive Summary
EU pivotal trials in relapsing-remitting multiple sclerosis should be structured as "active control parallel" studies, according to a guideline issued by the Committee for Proprietary Medicinal Products July 28.
You may also be interested in...
Serono Rebif Blocked By Orphan Exclusivity, FDA Says, But Timing Is Unclear
Serono has been informed by FDA that approval of its multiple sclerosis therapy Rebif is blocked by the orphan drug exclusivity of both Berlex' Betaseron and Biogen's Avonex, but has not been given a date for when that exclusivity will expire.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials